- Mediterranean Diet Could Keep Aging Brains Sharp
- Why Is Liver Cancer More Lethal for Black Patients?
- AHA News: Why Experts Say a Good Mood Can Lead to Good Health
- COVID Cases, Deaths Plummet in Nursing Homes After Vaccine Rollout
- Health Highlights: Feb. 25, 2021
- History of Mental Illness Tied to Earlier Onset of Alzheimer’s Disease
- Mental Illness Not a Factor in Most Mass Shootings
- High Blood Pressure in Pregnancy Could Affect Women’s Hearts Long Term
- Modern Medicine Unwraps Mystery of Ancient Mummy’s Death
- Pandemic Is Adding to Teachers’ Stress, and Quit Rates
Zyclara Approved to Treat Pre-Cancerous Skin Condition
FRIDAY, March 26Zyclara topical cream (imiquimod 3.75 percent) has been approved by the U.S. Food and Drug Administration to treat actinic keratoses (AKs), a precancerous condition that’s commonly found on skin frequently exposed to the sun.
AKs — sometimes confused with eczema or psoriasis — are small, red patches of skin that also may be scaly or rough, drug maker Graceway Pharmaceuticals said. They are most often found on the face, bald scalp, hands, shoulders and arms. Some 10 million Americans have the condition, which tends to recur, the company said in a news release.
AKs should be treated without delay, since they may progress to a form of skin cancer called squamous cell carcinoma. In clinical testing involving people with five to 20 AKs on the face or scalp, Zyclara reduced the total number of AKs by 82 percent, the news release said.
The most common side effects reported were local skin reactions with redness, scabbing or crusting, and sores or ulcers.
More information
To learn more about actinic keratoses, visit the Skin Cancer Foundation.
Source: HealthDay
